A re‐assessment of the role of combined androgen blockade for advanced prostate cancer
- 27 May 2004
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 93 (9), 1177-1182
- https://doi.org/10.1111/j.1464-410x.2004.04803.x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Design and analysis of non‐inferiority mortality trials in oncologyStatistics in Medicine, 2002
- An evaluation of bicalutamide in the treatment of prostate cancerExpert Opinion on Pharmacotherapy, 2002
- Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinomaCancer, 2002
- Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placeboAmerican Heart Journal, 2001
- Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trialsThe Lancet, 2000
- Analysis of exon 1 mutations in the androgen receptor geneHuman Mutation, 1999
- Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model systemBritish Journal of Cancer, 1999
- Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activityProstate Cancer and Prostatic Diseases, 1998
- Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate CancerThe New England Journal of Medicine, 1998
- Ligand-induced Conformational Alterations of the Androgen Receptor Analyzed by Limited TrypsinizationOnline Journal of Public Health Informatics, 1995